Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Cellgram-DC-PC in Metastatic Castration Resistant Prostate Cancer
NCT04615845Phase 1Terminated
- Sponsor
- Pharmicell Co., Ltd.
- Start
- Jul 2021
- Primary completion
- Feb 2022
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Cellgram-DC-PC in castration-resistant prostate cancer (CRPC), sponsored by Pharmicell Co., Ltd. Primary endpoint: Adverse Event at 28 weeks. Started Jul 2021; status: terminated.
02
Drugs
Cellgram-DC-PC
03
Conditions
castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on NCT04615845.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04615845.